Overview

Enhancing the A in SAFE for Trachoma

Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
This study will assess the cost and feasibility of two strategies of enhanced Mass Drug Administration (MDA) of Zithromax to treat trachoma in the Republic of South Sudan. The secondary objectives of this study are to measure trachoma infection outcomes during the 12-month follow-up period among children up to 9 years of age.
Phase:
Phase 4
Details
Lead Sponsor:
Emory University
Treatments:
Azithromycin